News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
256,328 Results
Type
Article (13721)
Company Profile (257)
Press Release (242350)
Section
Business (79145)
Career Advice (147)
Deals (13163)
Drug Delivery (28)
Drug Development (50142)
Employer Resources (31)
FDA (5633)
Job Trends (5103)
News (143570)
Policy (10010)
Tag
Academia (900)
Africa (145)
Allergies (30)
Alliances (21400)
Alzheimer's disease (684)
Antibody-drug conjugate (ADC) (31)
Approvals (5598)
Arizona (38)
Artificial intelligence (29)
Asia (16639)
Australia (2780)
Bankruptcy (96)
Best Places to Work (4347)
Biotechnology (215)
C2C Services and Suppliers (10603)
California (1217)
Canada (496)
Cancer (299)
Career advice (128)
CAR-T (33)
Cell therapy (93)
China (90)
Clinical research (39038)
Collaboration (85)
Colorado (37)
Compensation (40)
Connecticut (42)
COVID-19 (977)
Cystic fibrosis (58)
Data (226)
Diabetes (38)
Diagnostics (1157)
Earnings (28353)
Employer resources (29)
Europe (35681)
Events (45763)
Executive appointments (96)
FDA (5749)
Florida (120)
Funding (98)
Gene editing (28)
Gene therapy (80)
GLP-1 (262)
Government (1051)
Healthcare (6510)
Hotbed/Location (184111)
Illinois (74)
Indiana (43)
Infectious disease (986)
Inflammatory bowel disease (79)
IPO (7133)
Job creations (856)
Job search strategy (124)
Kansas (52)
Layoffs (177)
Legal (1369)
Lung cancer (70)
Manufacturing (28)
Maryland (184)
Massachusetts (990)
Medical device (2514)
Medtech (2515)
Mergers & acquisitions (6033)
Metabolic disorders (131)
Michigan (38)
Minnesota (65)
Neuroscience (791)
New Jersey (330)
New York (394)
NextGen Class of 2024 (1975)
Non-profit (837)
North Carolina (326)
Northern California (531)
Obesity (75)
Ohio (62)
Opinion (86)
Parkinson's disease (30)
Patents (35)
Pennsylvania (276)
People (24695)
Pharmaceutical (41)
Phase I (13693)
Phase II (18154)
Phase III (11549)
Pipeline (77)
Postmarket research (842)
Preclinical (5767)
Press Release (30)
Rare diseases (102)
Real estate (1405)
Regulatory (8018)
Research institute (928)
South America (206)
Southern California (505)
Startups (1963)
Texas (114)
United States (4659)
Vaccines (132)
Washington State (154)
Weight loss (59)
Date
Today (73)
Last 7 days (417)
Last 30 days (1370)
Last 365 days (21460)
2024 (15056)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
256,328 Results for "allecra therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Allecra Therapeutics and Acino Sign Exclusive Licensing and Supply Agreement for Allecra’s Novel Antibiotic EXBLIFEP® in Gulf Cooperation Council countries and South Africa
Allecra Therapeutics and Acino announced the signing of an exclusive licensing agreement under which Acino gains the rights to commercialise Allecra’s antibiotic drug EXBLIFEP® within the Republic of South Africa and the member states of the GCC alliance, which includes Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates, effective from 12 June 2024.
June 24, 2024
·
5 min read
FDA
Allecra Therapeutics Announces U.S. FDA Approval for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
Allecra Therapeutics, a biopharmaceutical company developing novel therapies to combat antibiotic resistance, announced that the U.S. Food and Drug Administration has approved EXBLIFEP®, as a treatment for complicated urinary tract infections, including pyelonephritis, in patients 18 years and older.
February 27, 2024
·
4 min read
Policy
Allecra Therapeutics Submits New Drug Application to the U.S. FDA for EXBLIFEP® for the Treatment of Complicated Urinary Tract Infections
Allecra Therapeutics announced the submission of a New Drug Application to the U.S. Food and Drug Administration for cefepime/enmetazobactam, an antibiotic combination of the fourth generation cephalosporin cefepime with the proprietary beta lactamase inhibitor, enmetazobactam, for the treatment of complicated urinary tract infections.
June 27, 2023
·
3 min read
Drug Development
Clinical Catch-Up: Adocia, Allecra and Aldeyra
Adocia, Allecra Therapeutics and Aldeyra Therapeutics announced promising results in Type I Diabetes, urinary tract infections and retinal diseases.
October 6, 2022
·
3 min read
·
Vanessa Doctor, RN
Business
Allecra Therapeutics and ADVANZ PHARMA Sign Exclusive License and Supply Agreement for Allecra’s Antibiotic Cefepime/enmetazobactam in Europe
ADVANZ PHARMA Corp. Limited and Allecra Therapeutics announced that the companies have signed an exclusive license agreement under which ADVANZ PHARMA gains the rights to develop and commercialize Allecra’s antibiotic drug candidate cefepime/enmetazobactam within the European Union, the United Kingdom, Switzerland, and Norway.
January 13, 2022
·
6 min read
Drug Development
Allecra Therapeutics Publishes Final Phase 3 ALLIUM Data in JAMA: Cefepime/Enmetazobactam Met Criteria for Superiority
Allecra Therapeutics announced that the final results from its Phase 3 ALLIUM trial investigating the combination of cefepime/enmetazobactam in patients with complicated urinary tract infections have been published in the Journal of the American Medical Association.
October 5, 2022
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Business
Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties
December 21, 2020
·
5 min read
Pharm Country
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc. announced that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024.
June 27, 2024
·
2 min read
Genetown
Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs
Inhibikase Therapeutics, Inc. today announced expansion of its therapeutic pipeline and multiple updates to its Research and Development programs.
June 5, 2024
·
6 min read
1 of 25,633
Next